Does the media prefer ELAN or GPCR?

In the previous week, Elanco Animal Health had 19 more articles in the media than Structure Therapeutics. MarketBeat recorded 31 mentions for Elanco Animal Health and 12 mentions for Structure Therapeutics. Elanco Animal Health's average media sentiment score of 0.77 beat Structure Therapeutics' score of -0.27 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 11 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CORT or GPCR?

In the previous week, Corcept Therapeutics had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 19 mentions for Corcept Therapeutics and 12 mentions for Structure Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat Structure Therapeutics' score of -0.27 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 12 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GPCR or AXSM?

In the previous week, Axsome Therapeutics had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 19 mentions for Axsome Therapeutics and 12 mentions for Structure Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat Structure Therapeutics' score of -0.27 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts prefer GPCR or RDY?

Structure Therapeutics presently has a consensus price target of $110.91, indicating a potential upside of 110.31%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 2 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 3 Strong Buy rating(s) 2.89 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer GPCR or RDY?

In the previous week, Structure Therapeutics had 5 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 12 mentions for Structure Therapeutics and 7 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Structure Therapeutics' score of -0.27 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Dr. Reddy's Laboratories 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Structure Therapeutics (GPCR) Competitors

$52.74 -0.40 (-0.76%)

As of 10:05 AM Eastern

Compare

GPCR vs. ELAN, CORT, AXSM, RDY, and CRNX

Should you buy Structure Therapeutics stock or one of its competitors? MarketBeat compares Structure Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Structure Therapeutics include Elanco Animal Health (ELAN), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceuticals" industry.

How does Structure Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Structure Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Structure Therapeutics	N/A	-26.12%	-24.85%

In the previous week, Elanco Animal Health had 19 more articles in the media than Structure Therapeutics. MarketBeat recorded 31 mentions for Elanco Animal Health and 12 mentions for Structure Therapeutics. Elanco Animal Health's average media sentiment score of 0.77 beat Structure Therapeutics' score of -0.27 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	11 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elanco Animal Health has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, indicating that its stock price is 243% less volatile than the broader market.

Structure Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.29	-$232M	-$0.41	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Elanco Animal Health currently has a consensus price target of $29.09, indicating a potential upside of 34.36%. Structure Therapeutics has a consensus price target of $110.91, indicating a potential upside of 110.31%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Elanco Animal Health beats Structure Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Corcept Therapeutics had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 19 mentions for Corcept Therapeutics and 12 mentions for Structure Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat Structure Therapeutics' score of -0.27 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	12 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corcept Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, meaning that its stock price is 243% less volatile than the broader market.

Corcept Therapeutics presently has a consensus target price of $119.17, suggesting a potential upside of 5.27%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 110.31%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Corcept Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.07	$99.65M	$0.42	269.54
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Corcept Therapeutics has a net margin of 6.52% compared to Structure Therapeutics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Structure Therapeutics	N/A	-26.12%	-24.85%

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Corcept Therapeutics beats Structure Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Axsome Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Structure Therapeutics has a beta of -1.43, meaning that its stock price is 243% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Structure Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Structure Therapeutics' return on equity of -26.12% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-26.12%	-24.85%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Structure Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Axsome Therapeutics	$638.50M	17.51	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 19 mentions for Axsome Therapeutics and 12 mentions for Structure Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat Structure Therapeutics' score of -0.27 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Structure Therapeutics currently has a consensus target price of $110.91, indicating a potential upside of 110.31%. Axsome Therapeutics has a consensus target price of $265.55, indicating a potential upside of 22.22%. Given Structure Therapeutics' higher possible upside, equities analysts clearly believe Structure Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Structure Therapeutics beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Structure Therapeutics (NASDAQ:GPCR) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Structure Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-26.12%	-24.85%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Structure Therapeutics presently has a consensus price target of $110.91, indicating a potential upside of 110.31%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Structure Therapeutics had 5 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 12 mentions for Structure Therapeutics and 7 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Structure Therapeutics' score of -0.27 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dr. Reddy's Laboratories	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Dr. Reddy's Laboratories	$3.58B	2.82	$456M	$0.44	27.44

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Structure Therapeutics has a beta of -1.43, indicating that its share price is 243% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Summary

Dr. Reddy's Laboratories beats Structure Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Structure Therapeutics (NASDAQ:GPCR) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Structure Therapeutics has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Crinetics Pharmaceuticals	$7.70M	1,158.92	-$465.32M	-$5.04	N/A

Structure Therapeutics currently has a consensus target price of $110.91, indicating a potential upside of 110.31%. Crinetics Pharmaceuticals has a consensus target price of $81.00, indicating a potential downside of 3.72%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Structure Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Structure Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Structure Therapeutics' return on equity of -26.12% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-26.12%	-24.85%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

In the previous week, Structure Therapeutics had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 12 mentions for Structure Therapeutics and 11 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.66 beat Structure Therapeutics' score of -0.27 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Structure Therapeutics has a beta of -1.43, indicating that its stock price is 243% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Structure Therapeutics beats Crinetics Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GPCR vs. The Competition

Export

Metric	Structure Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.78B	$11.86B	$7.02B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-53.17	788.48	269.90	24.97
Price / Sales	N/A	968.97	659.13	107.89
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	2.11	10.37	11.29	6.44
Net Income	-$141.20M	$2.77B	$3.45B	$347.50M
7 Day Performance	9.05%	2.47%	3.56%	3.82%
1 Month Performance	-1.17%	-1.08%	-0.57%	-0.37%
1 Year Performance	223.34%	191.49%	77.67%	23.81%

Structure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GPCR Structure Therapeutics	1.9362 of 5 stars	$52.74 -0.8%	$110.91 +110.3%	+225.8%	$3.78B	N/A	N/A	136	News Coverage Positive News Earnings Report Analyst Forecast Gap Up
ELAN Elanco Animal Health	4.3501 of 5 stars	$25.67 -2.6%	$28.73 +11.9%	+32.8%	$13.17B	$4.72B	N/A	9,400	Earnings Report
CORT Corcept Therapeutics	3.5786 of 5 stars	$112.54 -0.2%	$119.17 +5.9%	+53.2%	$12.31B	$761.41M	271.25	300	Gap Down
AXSM Axsome Therapeutics	3.6694 of 5 stars	$212.49 +0.7%	$261.29 +23.0%	+103.0%	$10.93B	$638.50M	N/A	380	Earnings Report Insider Trade
RDY Dr. Reddy's Laboratories	2.8546 of 5 stars	$12.03 -0.4%	N/A	-11.6%	$10.04B	$3.58B	27.33	27,527

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GPCR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Structure Therapeutics (GPCR) Competitors

GPCR vs. ELAN, CORT, AXSM, RDY, and CRNX

How does Structure Therapeutics compare to Elanco Animal Health?

Summary

How does Structure Therapeutics compare to Corcept Therapeutics?

Summary

How does Structure Therapeutics compare to Axsome Therapeutics?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Structure Therapeutics (GPCR) Competitors

GPCR vs. ELAN, CORT, AXSM, RDY, and CRNX

How does Structure Therapeutics compare to Elanco Animal Health?

Is ELAN or GPCR more profitable?

Does the media prefer ELAN or GPCR?

Which has more risk and volatility, ELAN or GPCR?

Which has stronger valuation & earnings, ELAN or GPCR?

Do institutionals & insiders believe in ELAN or GPCR?

Do analysts prefer ELAN or GPCR?

Summary

How does Structure Therapeutics compare to Corcept Therapeutics?

Does the media refer more to CORT or GPCR?

Which has more volatility & risk, CORT or GPCR?

Do analysts prefer CORT or GPCR?

Which has better earnings & valuation, CORT or GPCR?

Is CORT or GPCR more profitable?

Do institutionals and insiders hold more shares of CORT or GPCR?

Summary

How does Structure Therapeutics compare to Axsome Therapeutics?

Which has more volatility & risk, GPCR or AXSM?

Is GPCR or AXSM more profitable?

Which has preferable earnings and valuation, GPCR or AXSM?

Does the media prefer GPCR or AXSM?

Do analysts recommend GPCR or AXSM?

Do institutionals & insiders have more ownership in GPCR or AXSM?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Is GPCR or RDY more profitable?

Do analysts prefer GPCR or RDY?

Does the media prefer GPCR or RDY?

Which has preferable valuation & earnings, GPCR or RDY?

Do institutionals and insiders believe in GPCR or RDY?

Which has more risk & volatility, GPCR or RDY?

Summary

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Which has better earnings and valuation, GPCR or CRNX?

Do analysts rate GPCR or CRNX?

Is GPCR or CRNX more profitable?

Does the media prefer GPCR or CRNX?

Which has more risk and volatility, GPCR or CRNX?

Do institutionals & insiders believe in GPCR or CRNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools